ASX-LISTED cannabis company Medlab has announced intitial trials of its medicinal cannabis product NanaBis will commence at Royal North Shore Hospital in a few weeks.
Seriously ill oncology patients will be administered the product and results can be expected "several months later " and under The Therapeutic Goods Administration's Special Access Scheme, a drug could be approved later this year, the company has said.
Unique in its delivery, NanaBis will be delivered by, NanoCelle, Medlab's nano-particle spray to the back of the cheek, enabling easy delivery and improved speed of absorption.
A second cannabis medicine will enter a trial this year, a NanoCelle delivery form statin will be out in coming months and Phase II trials for bacteria-based medicines for depression and obesity will start.
Medlab is hosting a free evening seminar on 28 Feb at the Hyatt in Sydney - CLICK HERE to register.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Feb 18
